Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ester acc inhibitors and uses thereof

a technology of ester acc and inhibitors, which is applied in the direction of antibacterial agents, drug compositions, metabolic disorders, etc., can solve the problems of not providing the long-term health benefit needed for sustainable weight loss, t2dm, stroke and coronary heart disease, and dramatic reduction in quality of li

Inactive Publication Date: 2017-06-15
SCHRODINGER INC +1
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new invention that uses certain compounds and methods. The technical effect of this invention is that it provides other embodiments that can utilize these compounds and methods. Rather than being defined by specific examples, the scope of this invention is defined by the claims.

Problems solved by technology

Obesity also leads to social stigmatization and discrimination, which decreases quality of life dramatically.
Furthermore, about half of the obese population, and 25% of the general population, have metabolic syndrome, a condition associated with abdominal obesity, hypertension, increased plasma triglycerides, decreased HDL cholesterol, and insulin resistance, which increases the risk for type-2 diabetes (T2DM), stroke and coronary heart disease.
Diet and exercise, even when used in conjunction with the current pharmacotherapy, do not provide sustainable weight loss needed for long-term health benefit.
Unfortunately, poor efficacy and unappealing gastrointestinal side effects limit the use of orlistat.
Surgery can be effective but is limited to patients with extremely high body-bass indices (BMI) and the low throughput of surgery limits the impact of this modality to about 200 k patients per year.
However, the FDA has taken an unfavorable position against CNS-active agents, due to their modest efficacy and observed / potential side-effect profiles.
Another ongoing problem is the lack of antifungal drugs with activity against a broad range of fungal pathogens.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ester acc inhibitors and uses thereof
  • Ester acc inhibitors and uses thereof
  • Ester acc inhibitors and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

of ethyl (R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate, I-3

[0429]

[0430]Synthesis of Compound 1.2.

[0431]Into a 3000-mL 3-necked round-bottom flask under nitrogen, was placed DMSO (1400 mL). This was followed by the addition of NaH (25.0 g, 625.0 mmol, 1.22 equiv, 60%). The mixture was stirred for 15 min at room temperature. To this was added trimethylsulfoxonium iodide (136.0 g, 617.9 mmol, 1.2 equiv.), in portions at room temperature over 30 min. The resulting solution was stirred for 3 h at 40° C. To the mixture was added compound 1.1 (70.0 g, 514.2 mmol, 1.00 equiv) dropwise with stirring at 15° C. The reaction was stirred for 3 hours at room temperature, then quenched by the addition of 1500 mL of NH4Cl (aq.). The resulting solution was extracted with 2×1000 mL of EtOAc, and the organic layers were combined, dried over anhydrous Na2SO4 ...

example 2

of ethyl (R)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate, I-1

[0456]

[0457]Compound I-1 was synthesized from compound 1.95 and ethylamine hydrochloride using procedure described in Example 1. LC-MS (ES, m / z): [M-C2H6N]+ 557, [M+Na]+ 624; 1H NMR (400 MHz, DMSO-d6): δ 0.95-1.05 (t, 3H), 1.15-1.30 (m, 1H), 1.33-1.35 (t, 3H), 1.64-1.67 (m, 8H), 2.74 (s, 3H), 3.05-3.08 (m, 2H), 3.24-3.33 (m, 3H), 3.48-3.65 (m, 2H), 3.80 (s, 3H), 3.90-4.10 (m, 2H), 4.29-4.34 (m, 2H), 5.26-5.29 (t, 1H), 7.00-7.07 (m, 2H), 7.33-7.35 (m, 1H), 7.48-7.55 (m, 2H).

example 3

of ethyl (R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(piperidin-1-yl)propan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate, I-2

[0458]

[0459]Compound I-2 was synthesized from compound 1.95 and piperidine using procedure described in Example 1. LC-MS (ES, m / z): [M-C5H10N]+ 557; 1H NMR (400 MHz, CD3OD): δ 1.35-1.42 (m, 6H), 1.46-1.82 (m, 13H), δ 2.80 (s, 3H), 3.33-3.81 (m, 9H), 3.88 (s, 3H), 4.00-4.25 (m, 1H), 4.34-4.40 (m, 2H), 5.40 (t, 1H), 7.02-7.06 (m, 2H), 7.31-7.35 (m, 1H), 7.51-7.52 (m, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides ester compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 259,975, filed on Nov. 25, 2015, the entirety of which is incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Obesity is a health crisis of epic proportions. The health burden of obesity, measured by quality-adjusted life-years lost per adult, has surpassed that of smoking to become the most serious, preventable cause of death. In the US, about 34% of adults have obesity, up from 31% in 1999 and about 15% in the years 1960 through 1980. Obesity increases the rate of mortality from all causes for both men and women at all ages and in all racial and ethnic groups. Obesity also leads to social stigmatization and discrimination, which decreases quality of life dramatically. The chronic diseases that result from obesity cost the US economy more than $150 billion in weight-related medical bills each year. Furthermore, about half of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D495/04A01N43/90
CPCC07D495/04A01N43/90A61P3/04A61P31/04A61P31/10A61P33/00A61P43/00A61P3/10C07D487/04C07D491/048
Inventor GHOSH, SHOMIRGREENWOOD, JEREMY ROBERTHARRIMAN, GERALDINE C.LEIT DE MORADEI, SILVANA MARCEL
Owner SCHRODINGER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com